Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance

“Instead of fighting tumor adaptation, we are using it to guide our design.”Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Ya-Chi Chen, Chief Scientific Officer, OBI Pharma, about the design of a bispecific, dual-payload ADC, and how this strategy aims to address tumor resistance, heterogeneity, and payload limitations in difficult-to-treat cancers.